OCT 10, 2018 7:30 AM PDT

Keynote Presentation: Proteogenomics and Cancer Biology: Insights for Prognosis and Therapy

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director and Professor, Biological Sciences Division, Pacific Northwest National Laboratory
    Biography
      Dr. Karin Rodland joined the Biological Sciences Division at the Pacific Northwest National Laboratory in October 2001, after serving seventeen years on the faculty of Oregon Health Sciences University. As Chief Scientist for Biomedical Research at PNNL, she has promoted the application of PNNL's traditional strengths in mass spectrometry, proteomics, and systems biology to important problems in biomedical research. She is currently the PNNL co-Director of the OHSU-PNNL Precision Medicine Innovation CoLaboratory, a joint effort dedicated to improving patient outcomes through the integration of cutting edge technologies in integrated omics, imaging, and data analysis to advance the goals of precision medicine.
      Dr. Rodland's own research focuses on signal transduction pathways that regulate proliferation in normal and malignant cells. She was the first to recognize the role of the calcium-sensing receptor in modulating proliferation in response to small molecules in the extracellular environment. Since joining PNNL, she has adopted a systems biology approach to signal transduction and has become a recognized expert in the field of proteomics and cancer biomarkers. She is a full member of the National Cancer Institute's Early Detection Research Network, and is the chair of the Clinical Proteomics Tumor Analysis Consortium Steering Committee. She has served as Chair of the Cancer Biomarkers Study Section for the NIH, as well as the Department of Defense Congressionally Directed Medical Research Program Integration Panels for both Ovarian and Breast Cancer Research.

    Abstract

    Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids – DNA, RNA and their modifications – and a focus on proteins and protein function. Proteogenomics represents a fusion of those two approaches, leveraging the strengths of each to provide a more integrated vision of the flow of information from DNA to RNA to protein and eventually function at the molecular level. Proteogenomic studies have been incorporated into multiple activities associated with precision oncology, demonstrating substantial added value. Innovative study designs integrating genomic, transcriptomic and proteomic data, particularly those using clinically relevant samples and involving clinical trials, are poised to provide new insights regarding cancer risk, progression, and response to therapy.

    Learning Objectives: 

    1. Understand the value-added of including protein measurements with genomics and transcriptomics
    2. Understand the importance of pathway-level analysis


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    Loading Comments...
    Show Resources
    Attendees
    • See more